Company intelligence / Profile preview

Number 8 Bio

Sydney, New South Wales, Australianumber8.bio ↗

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

Lab studies show up to a 90% reduction in enteric methane emissions from livestock with their feed additive. The company claims up to a 12% increase in feed efficiency and a strong ROI for farmers. Cattle trials are planned as the next step before full commercialization.

Therapeutic areas: Other
Modalities: Engineered microbes (yeast)fermentation-based feed additives
Industry: Non-Drug Biotech

Drug pipeline

1 asset

BetterFeed

Pre-clinical

Indications: Livestock methane emissions reduction

Partnerships

Seeking R&D partnerships with leading beef, sheep, and dairy brands. No major pharma/biotech partnerships disclosed yet.

Beyond the preview

Go deeper on Number 8 Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Number 8 Bio.

Explore the full profile